Study guide
13.3 Clinical Pharmacogenomics (PGx) Core Alleles
ASCP Molecular Biology Technologist MB
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Strategy
1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy
2 Nucleic Acid Chemistry & Molecular Structure
2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation
3 Central Dogma, Genome Organization & Cytogenetics
3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations
4 Biochemical Reagents & Enzymes
4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives
5 Nucleic Acid Isolation & Purification
5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices
6 Nucleic Acid Quantification & Electrophoresis
6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics
7 PCR Principles & Primer Design Optimization
7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting
8 Advanced Amplification Technologies
8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification
9 DNA Sequencing Technologies
9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
10 Hybridization, Blotting & Cytogenetic Assays
10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)
11 Molecular Infectious Disease Diagnostics
11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing
12 Molecular Oncology & Hematopathology
12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease
13 Medical Genetics, Pharmacogenomics & Identity Testing
13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism
14 Quality Assurance, Controls & Method Validation
14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency
15 Laboratory Operations, Safety & Clinical Variant Reporting
15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS
13.3 Clinical Pharmacogenomics (PGx) Core Alleles
Key Takeaways Explain This Topic AI
Pharmacogenomics utilizes star-allele (*allele) nomenclature to classify Phase I/II drug-metabolizing enzymes, drug transporters, and HLA loci into Poor, Intermediate, Normal, Rapid, and Ultrarapid Metabolizer phenotypes.
CYP2D6 is a highly polymorphic Phase I enzyme with loss-of-function (*4, *5), decreased function (*10, *17, *41), and gene duplication (*1xN, *2xN) alleles; Ultrarapid Metabolizers convert codeine to morphine excessively, risking fatal toxicity.
CYP2C19 loss-of-function variants (*2, 3) prevent bioactivation of the prodrug clopidogrel (Plavix), leading to antiplatelet treatment failure and stent thrombosis, whereas CYP2C19 17 confers increased transcription.
Warfarin dosing requires combinatorial genotyping of CYP2C9 (*2, *3 impair S-warfarin clearance) and VKORC1 (-1639G>A reduces target enzyme expression), where variant carriers require substantially lower starting doses.
Dihydropyrimidine dehydrogenase (DPYD *2A) and thiopurine methyltransferase (TPMT *2, *3A, *3C) / NUDT15 (*3) deficiencies cause lethal toxicity upon exposure to standard doses of 5-fluorouracil and thiopurines, respectively.
Last updated: August 2026
13.3 Clinical Pharmacogenomics (PGx) Core Alleles
Quick Summary: Clinical Pharmacogenomics (PGx) investigates how inherited germline genomic variations modulate inter-individual drug absorption, distribution, metabolism, and elimination ( ADME ), as well as therapeutic efficacy and adverse drug reactions ( ADRs ). Variations are categorized using the standardized star-allele ( * \text{*} * ) nomenclature curated by the Pharmacogene Variation Consortium (PharmVar) and translated into clinical guidelines by the Clinical Pharmacogenetics Implementation Consortium (CPIC) . Key clinical targets include Phase I Cytochrome P450 enzymes ( CYP2D6 , CYP2C19 , CYP2C9 ), Phase II conjugating enzymes ( TPMT , NUDT15 , DPYD , UGT1A1 ), drug transporters ( SLCO1B1 ), and Human Leukocyte Antigen (HLA) alleles ( HLA-B*57:01 , HLA-B*15:02 , HLA-B*58:01 ).
1. Pharmacogenomic Foundations, Star-Allele Nomenclature & Phenotypes +----------------------------------------------------------------------------------------------------+
- | STAR-ALLELE (\*) FUNCTIONAL SCORING |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Functional Group | Assigned Activity | Hallmark Star (\*)| Biochemical & In Vivo Consequence |
- | | Score per Allele | Allele Examples | |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **Reference / | **1.0** | **\*1** | Fully functional wild-type enzyme |
- | Normal Function** | | | activity; standard baseline |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **Decreased | **0.5** (or 0.25) | **CYP2D6\*10, | Partial activity; missense changes |
- | Function** | | \*17, \*41; | impairing substrate affinity or |
- | | | CYP2C9\*2** | splicing efficiency |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **No Function / | **0.0** | **CYP2D6\*3, \*4, | Total absence of active enzyme; |
- | Null Allele** | | \*5; CYP2C19\*2, | frameshift, premature stop, canonical |
- | | | \*3; DPYD\*2A** | splice defect, or whole-gene deletion |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **Increased | **> 1.0** (or gene| **CYP2C19\*17; | Promoter gain-of-function mutations or |
- | Function** | copy multiplier) | CYP2D6\*1xN, \*2xN| genomic tandem gene duplications |
+-------------------+-------------------+-------------------+----------------------------------------+ Total Gene Activity Score (AS) = Activity ( Allele 1 ) + Activity ( Allele 2 ) \text{Total Gene Activity Score (AS)} = \text{Activity}(\text{Allele 1}) + \text{Activity}(\text{Allele 2}) Total Gene Activity Score (AS) = Activity ( Allele 1 ) + Activity ( Allele 2 ) +----------------------------------------------------------------------------------------------------+
- | METABOLIZER PHENOTYPE STRATIFICATION |
- +-------------------+-------------------+------------------------------------------------------------+
- | Phenotype Category| Activity Score | In Vivo Drug Dynamics & Clinical Impact |
- +-------------------+-------------------+------------------------------------------------------------+
- | **Poor | **AS = 0.0** | **Active Drug**: Toxic drug accumulation -> Reduce dose. |
- | Metabolizer (PM)**| (Two null alleles)| **Prodrug**: Inability to bioactivate -> Therapeutic failure|
- +-------------------+-------------------+------------------------------------------------------------+
- | **Intermediate | **AS = 0.5 to 1.0**| Reduced clearance; modest risk of toxicity or reduced |
- | Metabolizer (IM)**| (Decreased/null) | prodrug activation; often requires moderate dose titration |
- +-------------------+-------------------+------------------------------------------------------------+
- | **Normal / Exten- | **AS = 1.25 to | Standard therapeutic drug clearance and expected bio- |
- | sive (NM / EM)** | 2.0** | activation; standard dosing per manufacturer label |
- +-------------------+-------------------+------------------------------------------------------------+
- | **Rapid / Ultra- | **AS > 2.0** | **Active Drug**: Hyper-clearance -> Subtherapeutic efficacy|
- | rapid (RM / UM)** | (Gain/Duplication)| **Prodrug**: Rapid conversion -> Severe acute overdose risk|
+-------------------+-------------------+------------------------------------------------------------+ ACTIVE DRUG VS. PRODRUG METABOLIC DYNAMICS
- [ ACTIVE PARENT DRUG ] ----(CYP Metabolism)----> [ INACTIVE METABOLITE ]
- * Poor Metabolizer: Drug accumulation -> Severe Toxicity! (Lower Dose Needed)
- * Ultrarapid Metabolizer: Rapid clearance -> Therapeutic Failure! (Higher Dose Needed)
- [ INACTIVE PRODRUG ] ----(CYP Bioactivation)--> [ ACTIVE PHARMACOLOGICAL AGENT ]
- * Poor Metabolizer: Zero active drug formed -> Therapeutic Failure! (Switch Drug!)
- * Ultrarapid Metabolizer: Massive burst of active drug -> Fatal Toxicity! (Contraindicated!)
2. The Core Cytochrome P450 Enzymes: CYP2D6 , CYP2C19 , and CYP2C9 +----------------------------------------------------------------------------------------------------+
- | MAJOR CYTOCHROME P450 PHARMACOGENES |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Gene & Chromosome | Common Star (\*) | Substrate Drugs | Key Clinical Consequences & Guidance |
- | | Alleles & Nature | | |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **CYP2D6** | **\*1** (Normal) | **Codeine, | **Prodrugs (Codeine/Tramadol/Tamoxifen)**:|
- | (22q13.2) | **\*4** (Splice) | Tramadol, | PMs have no analgesia / poor endocrine |
- | Non-inducible; | **\*5** (Deletion)| Tamoxifen, | response. UMs have **fatal morphine |
- | >100 alleles; | **\*10, \*17, \*41| Fluoxetine, | overdose**; codeine contraindicated in |
- | Pseudogenes | **\*1xN, \*2xN** | Metoprolol, | nursing mothers and pediatric tonsil- |
- | *CYP2D7/8* | (Duplications) | Venlafaxine** | lectomy patients |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **CYP2C19** | **\*1** (Normal) | **Clopidogrel | **Clopidogrel (Prodrug)**: PMs and IMs |
- | (10q23.33) | **\*2** (Splice) | (Plavix), | (\*2, \*3) fail to form active thiol |
- | Highly polymorphic| **\*3** (Stop) | Omeprazole (PPIs),| metabolite -> High risk of stent throm-|
- | in East Asians | **\*17** (Promoter| Citalopram, | bosis; CPIC mandates alternative |
- | | Gain) | Voriconazole** | antiplatelet (Prasugrel, Ticagrelor) |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **CYP2C9** | **\*1** (Normal) | **Warfarin | S-warfarin is 3–5x more potent than |
- | (10q23.33) | **\*2** (Arg144Cys)| (S-enantiomer), | R-warfarin. \*2 and \*3 carriers have |
- | Major hepatic | **\*3** (Ile359Leu)| Phenytoin, | severely impaired clearance -> Extreme |
- | Phase I enzyme | | Celecoxib** | bleeding risk on standard doses |
- +-------------------+-------------------+-------------------+----------------------------------------+
- Molecular Challenges in CYP2D6 Testing
Testing CYP2D6 is technically demanding due to the adjacent pseudogenes CYP2D7 and CYP2D8 , which share > 90 % >90\% > 90% sequence homology. Gene conversions, hybrid genes (e.g., CYP2D6/CYP2D7 fusions), whole-gene deletions ( *5 ), and high-order copy number amplifications ( *1xN , *2xN , *4xN ) require combining Long-Range PCR (XL-PCR) , Multiplex Ligation-dependent Probe Amplification (MLPA) , or quantitative TaqMan Copy Number Assays (CNV) to avoid miscalling duplications of inactive alleles.
3. Warfarin Sensitivity: The CYP2C9 , VKORC1 , and CYP4F2 Dosing Triad
Warfarin is a narrow therapeutic index anticoagulant administered as a racemic mixture of R R R - and S S S -enantiomers. Inter-individual therapeutic maintenance dose requirements vary up to 10-fold across patients. WARFARIN PHARMACOGENOMIC MECHANISM
- S-Warfarin (Potent) Dietary Vitamin K
- | |
- v (CYP2C9 Inactivation) v
- Inactive Hydroxy-Warfarin Vitamin K Epoxide (Inactive)
- | ^
- | | (Inhibited by Warfarin!)
- VKORC1 Reductase |
- | |
- v |
- Vitamin K Hydroquinone (Active)
- |
- v (GGCX Carboxylation)
- Clotting Factors II, VII, IX, X
- (Functional Anticoagulation!)
CYP2C9 ( *2, *3 ) : Inactivates potent S S S -warfarin via 7-hydroxylation. The ∗ 2 *2 ∗ 2 (c.430C>T) and ∗ 3 *3 ∗ 3 (c.1075A>C) alleles reduce enzymatic activity by ∼ 30 % \sim 30\% ∼ 30% and ∼ 80 – 90 % \sim 80–90\% ∼ 80–90% , respectively, prolonging S S S -warfarin half-life.
VKORC1 (c.-1639G>A, rs9923231) : Located in the promoter region of Vitamin K Epoxide Reductase Complex Subunit 1 on chromosome 16p11.2 . The variant A A A allele suppresses transcription factor binding, reducing baseline VKORC1 protein expression. Individuals harboring A / A A/A A / A or G / A G/A G / A genotypes require significantly lower warfarin doses to achieve therapeutic target INR ( 2.0 – 3.0 2.0–3.0 2.0–3.0 ).
CYP4F2 (c.1297G>A, p.Val433Met, *3 ) : Removes vitamin K from the cycle by converting vitamin K 1 \text{K}_1 K 1 to hydroxyvitamin K 1 \text{K}_1 K 1 . The ∗ 3 *3 ∗ 3 variant reduces enzyme activity, shunting more vitamin K toward clotting factor activation and requiring slightly higher warfarin maintenance doses.
4. Phase II Enzymes & Chemotherapy Pharmacogenomics +----------------------------------------------------------------------------------------------------+
- | CHEMOTHERAPY PHARMACOGENOMICS & SEVERE TOXICITY GENES |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Gene & Enzyme | Critical Alleles | Drug Substrates | Clinical Manifestation & Guidelines |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **TPMT** | **\*2** (c.238G>C)| **6-Mercaptopurine| Inactivates thiopurines by S-methyl- |
- | (6p22.3) | **\*3A** (c.460A+ | (6-MP), | ation. Homozygous null or compound |
- | S-methyltransferase| c.719G in cis) | Azathioprine (AZA)| heterozygotes shunt drugs into cyto- |
- | | **\*3C** (c.719A>G)| 6-Thioguanine (6TG)| toxic TGNs -> **Lethal bone marrow |
- | | | | aplasia / pancytopenia**; reduce dose |
- | | | | by 90% or switch agents |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **NUDT15** | **\*3** | **6-Mercaptopurine| Hydrolyzes toxic thiopurine triphos- |
- | (13q14.2) | (c.415C>T, | Azathioprine** | phates (dTGTP); **Primary genetic |
- | Nudix Hydrolase | p.Arg139Cys) | | driver of thiopurine-induced leukopenia|
- | | | | in East Asians & Hispanics** |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **DPYD** | **\*2A** (c.1905+1| **5-Fluorouracil | Rate-limiting catabolic enzyme (>80% of|
- | (1p21.3) | G>A splice) | (5-FU), | 5-FU cleared by DPYD). Non-functional |
- | Dihydropyrimidine | **\*13** (c.1679T>G)| Capecitabine** | alleles cause drug accumulation -> |
- | Dehydrogenase | **c.2846A>T** | | **Fatal neurotoxicity, mucositis, |
- | | **HapB3** | | myelosuppression, and diarrhea** |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **UGT1A1** | **\*28** | **Irinotecan | Glucuronidates active SN-38 metabolite.|
- | (2q37.1) | (c.-53_-52insTA, | (Camptosar)** | Homozygous \*28/\*28 (TA)7/(TA)7 alleles|
- | Glucuronosyl- | (TA)$_7$ promoter | | (Gilbert syndrome) have impaired SN-38 |
- | transferase | vs (TA)$_6$ \*1) | | clearance -> **Severe neutropenia & |
- | | | | life-threatening diarrhea** |
- +-------------------+-------------------+-------------------+----------------------------------------+
- 5. HLA-Mediated Severe Cutaneous Adverse Reactions (SCAR) & Transporters
Severe, life-threatening idiosyncratic drug reactions are frequently mediated by specific Human Leukocyte Antigen (HLA) class I alleles that bind small-molecule drugs directly in the antigen-binding groove, triggering massive cytotoxic T-cell attacks against skin and viscera ( Stevens-Johnson Syndrome [SJS] , Toxic Epidermal Necrolysis [TEN] , and Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] ). +----------------------------------------------------------------------------------------------------+
- | HLA PHARMACOGENOMIC CONTRAINDICATIONS & TRANSPORTER GENES |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Pharmacogene | Associated Drug | Population Risk | Clinical Mandate & Pathology |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **HLA-B\*57:01** | **Abacavir** | Pan-ethnic | **Abacavir Hypersensitivity (AHR)**: |
- | | (Ziagen / Triumeq | (~5–8% Caucasians)| Multi-organ immune reaction; **Testing |
- | | for HIV-1)** | | is mandatory before prescribing; |
- | | | | 100% negative predictive value** |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **HLA-B\*15:02** | **Carbamazepine** | Southeast Asians, | **SJS / TEN**: Severe epidermolysis; |
- | | (Tegretol), | Han Chinese | FDA black-box warning; mandatory test |
- | | Oxcarbazepine | (10–15% prevalence)| in high-prevalence Asian ancestry |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **HLA-A\*31:01** | **Carbamazepine** | Caucasians, | **DRESS / SJS / Maculopapular exanthem**|
- | | | Japanese | Broad hypersensitivity spectrum |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **HLA-B\*58:01** | **Allopurinol** | Han Chinese, | **Allopurinol SCAR / SJS / DRESS**: |
- | | (Zyloprim for | Koreans, Thai | Severe cutaneous reactions in gout |
- | | gout/hyperuricemia)| (~10–15%) | patients; strongly recommended screen |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | **SLCO1B1** | **Simvastatin** | Pan-ethnic | Encodes OATP1B1 hepatic uptake pump; |
- | (12p12.1) | (Zocor), | (\*5 allele freq | \*5 (c.521T>C) impairs hepatic uptake, |
- | *SLCO1B1\*5* | Atorvastatin | $\sim 15\%$) | elevating systemic blood levels -> |
- | (p.Val174Ala) | | | **Severe statin-induced rhabdomyolysis**|
- +-------------------+-------------------+-------------------+----------------------------------------+